454 related articles for article (PubMed ID: 26959069)
1. Acute Myeloid Leukemia: A Concise Review.
Saultz JN; Garzon R
J Clin Med; 2016 Mar; 5(3):. PubMed ID: 26959069
[TBL] [Abstract][Full Text] [Related]
2. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Cancer Genomics Proteomics; 2016 09-10; 13(5):317-29. PubMed ID: 27566651
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic options in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Leuk Res Rep; 2016; 6():39-49. PubMed ID: 27752467
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and Therapy of Acute Myeloid Leukemia].
Medinger M; Heim D; Halter JP; Lengerke C; Passweg JR
Ther Umsch; 2019; 76(9):481-486. PubMed ID: 32157963
[TBL] [Abstract][Full Text] [Related]
5. Advances in understanding the biology and genetics of acute myelocytic leukemia.
McKenzie SB
Clin Lab Sci; 2005; 18(1):28-37. PubMed ID: 15747784
[TBL] [Abstract][Full Text] [Related]
6. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
Han TJ; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukaemia.
Khwaja A; Bjorkholm M; Gale RE; Levine RL; Jordan CT; Ehninger G; Bloomfield CD; Estey E; Burnett A; Cornelissen JJ; Scheinberg DA; Bouscary D; Linch DC
Nat Rev Dis Primers; 2016 Mar; 2():16010. PubMed ID: 27159408
[TBL] [Abstract][Full Text] [Related]
9. Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.
Konig H; Santos CD
Curr Cancer Drug Targets; 2015; 15(9):803-21. PubMed ID: 26278711
[TBL] [Abstract][Full Text] [Related]
10. Evolving treatment strategies in patients with high-risk acute myeloid leukemia.
Schiller GJ
Leuk Lymphoma; 2014 Nov; 55(11):2438-48. PubMed ID: 24432896
[TBL] [Abstract][Full Text] [Related]
11. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
[TBL] [Abstract][Full Text] [Related]
12. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
13. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
14. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
Kogan AA; Lapidus RG; Baer MR; Rassool FV
Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
16. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
17. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing of acute myeloid leukemia: influencing prognosis.
Ilyas AM; Ahmad S; Faheem M; Naseer MI; Kumosani TA; Al-Qahtani MH; Gari M; Ahmed F
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S5. PubMed ID: 25924101
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-risk acute myeloid leukemia therapy: current and future.
Döhner K; Paschka P
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):34-43. PubMed ID: 25696832
[TBL] [Abstract][Full Text] [Related]
20. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
